REGENXBIO Rings the Opening Bell

About This Event

REGENXBIO (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, visits the Nasdaq MarketSite in Times Square to ring the opening bell to commemorate the company's seventh anniversary of going public.

In honor of the occasion, Ken Mills, CEO of REGENXBIO, rings the Opening Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore